Alzheimer’s Therapeutic Market By Drug Name (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine and Donepezil) By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Manufactured Combination) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) - Growth, Share, Opportunities & Competitive Analysis, 2016 – 2028

How Rising Prevalence of Prevalence of Target Diseases and Increasing Geriatric Population Supported the Growth of Alzheimer’s Therapeutic Market?

The global Alzheimer’s therapeutics market is increasing considerably as a result of the increasing prevalence and incidence rates of this illness and also the growing geriatric population base. The World Health Organization (WHO) estimates that 50 million people have Alzheimer's disease in 2021, with about 10 million new cases being diagnosed each year. It mainly affects adults over the age of 65. Additionally, it is anticipated that increased awareness of its symptoms, such as partial dementia, will increase demand. The total cost of Alzheimer's disease is rising as more expensive medications and treatments are being used to manage the condition. The National Library of Medicine estimates that by 2030, the expense of Alzheimer's disease to the world economy will rise from USD 818 billion to USD 2 trillion.

alzeimers-therapeutic-market.img1

What is the Market Size of the Alzheimer’s Therapeutic Market in terms of value?

Global Alzheimer’s Therapeutic Market is projected to increase at a significant CAGR of 9.1% in the coming years. In 2021, the global Alzheimer’s Therapeutic market was valued at USD 2491.5 million and is projected to reach the value of USD 4201.54 million by 2028. The demand for Alzheimer’s Therapeutic is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD 1710.04 million over the forecast period between 2022 and 2028.

How Technological Advancements for the Development of Innovative Drugs Play an Important Role in Alzheimer’s Therapeutic Market?

Growing investment in R&D activities and technical developments for the creation of innovative medications and techniques for the treatment of Alzheimer's disease are contributing to the market expansion of the Alzheimer’s Therapeutic market.  The sale of Alzheimer's treatments is increasing due to the increased use of generic pharmaceuticals such as Donepezil by people, as well as the greater use of biomarkers in Alzheimer's diagnosis and therapy research. Numerous studies are being conducted worldwide to develop diagnostic tools for the treatment of Alzheimer's. New technologies are helpful in the diagnosis and treatment of Alzheimer's disease in addition to the conventional therapeutic approaches. The global market for therapeutics for Alzheimer's disease is expected to grow over the forecast period as a result of rising healthcare awareness and better diagnostic tools for the condition. The National Institute on Aging reports that more than 25 new genes are implicated in Alzheimer's disease and are important in its management. Researchers are identifying potential targets for medications and non-drug therapies to treat or stop the disease by figuring out these pathways.

Interesting Facts about Alzheimer’s Therapeutic Industry

  • Alzheimer's is a form of dementia that affects the patient's behaviour, thinking, and memory. The disease is steadily progressing, but the neurons in the area of the brain responsible for learning are deteriorating. It is the most prevalent type of dementia in adults over 65.
  • The increased incidence and prevalence of Alzheimer's disease, expanding public health awareness about the condition, and the development of breakthrough technologies and treatments to extend life expectancy are all driving significant growth in the market.
  • Late-stage medication failures, an absence of surrogate markers for drug discovery and development, insufficient research funding, and lengthy unclear processes are projected to hinder growth in the global Alzheimer's Therapeutic market during the forecast period.
  • North America region had a major share in terms of volume as well as value in the global Alzheimer’s Therapeutic market in 2021 and is projected to continue its dominance over the forecast period.
  • Cholinesterase Inhibitors segment to witness high growth during the forecast period as they are frequently utilized by healthcare practitioners to address disorders linked to memory, thinking, language, judgment, and other thought processes.

Who are the Top 10 players/companies in Alzheimer’s Therapeutic market in terms of value and volume?

The key players in the global Alzheimer’s Therapeutic market in terms of value and volume include AbbVie Inc., Lannett Inc., Teva Pharmaceuticals Ltd, Unichem laboratories Ltd, Eisai Co. Ltd, Torrent Pharmaceuticals Ltd, Janssen Pharmaceuticals Inc. (Johnson & Johnson), Cipla Ltd, Novartis AGNovartis AG, Lupin Ltd, Zydus Lifesciences Ltd (CADILA), Viatris Inc, Sun Pharmaceutical Industries Ltd, Macleods Pharmaceuticals Ltd, Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, and Amneal Pharmaceuticals Inc. These key players are concentrating on new product developments as well as technological innovation to enhance their production of Alzheimer’s Therapeutics to gain competitive market share at a global level. For instance, in March 2022, Biogen Inc. and Eisai Co. Ltd. expanded their existing partnership deal for Alzheimer's disease treatments. On the other hand, in November 2021, Brigham and Women's Hospital in Boston, Massachusetts, has begun a clinical trial to evaluate the safety and efficacy of a new nasal vaccine for Alzheimer's disease.

Who are the Top 10 Countries in the Alzheimer’s Therapeutic Market?

In the global Alzheimer’s Therapeutic market, the major countries are China, India, the U.S., Canada, the U.K., Germany, France, Russia, Switzerland, Japan, and Australia. The U.S. is the most profitable market for Alzheimer's therapeutics due to the region's increasing prevalence of Alzheimer's disease and other types of dementia, as well as significant investment in research and development activities and the launch of new products. Also, China holds a 41.2% of the East Asian market for Alzheimer's Therapeutic market as of 2021 owing to the country's fast-developing medical infrastructure, an increase in scientific research into the diagnosis, treatment, and monitoring of the disease, as well as significant investment from both the public and commercial sectors for Alzheimer's research.

Which is the Key Application Area in the Alzheimer’s Therapeutic Market?

The cholinesterase inhibitors segment has the highest revenue share of the global Alzheimer's Therapeutics market in 2021 and is expected to dominate the market over the forecast period since they are commonly used by healthcare professionals to treat symptoms associated with memory, thinking, language, judgment, and other thought processes. This is propelling the market.

In addition, in Alzheimer's disease, there has been a rise in the applications of various machine learning approaches, most commonly with imaging data, for diagnosis and disease progression. This includes, among other things, amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping. For instance, researchers from the VA healthcare systems in Bedford and Boston created a non-invasive optical technique that aids in the diagnosis of Alzheimer's disease. This novel method employs spectroscopy to detect structural changes in the brain. This technological advancement has evolved to meet the needs of people living with dementia, informal caregivers, formal caregivers, and social caregivers, creating a massive opportunity in the Alzheimer's therapeutics market.

What are the Major Driving Factors for Alzheimer’s Therapeutic Market?

The Global Alzheimer’s Therapeutic Market is predicted to experience exceptional growth over the forecast years attributable to the increasing demand for minimally invasive procedures in the treatment of Alzheimer’s illness. The rising incidence and prevalence of Alzheimer's disease, rising public health awareness about the disease, and the introduction of novel technologies and drugs to improve life expectancy are all driving significant growth in the Global Alzheimer's Therapeutic market. Growing investment in R&D activities and technological developments for the creation of novel drugs and methods for the treatment of Alzheimer's disease are also contributing to the market growth. Moreover, the global aging population, growth in the healthcare sector, and increased government initiatives and support in the form of funds and grants to enhance diagnostic techniques and treatment procedures all contribute to the growth of the Alzheimer's Therapeutic market.

What are the Major Restraints for Alzheimer’s Therapeutic Market?

Late-stage drug failures, an absence of surrogate markers for drug discovery and development, inadequate research funding, and lengthy uncertain processes are expected to suppress growth in the global Alzheimer's Therapeutic market throughout the forecast period. Many Alzheimer's therapies, including donepezil and others, have been phased out in recent years. According to the National Library of Medicine, donepezil was discontinued in 2021 due to adverse effects on patients, which was the primary reason for its discontinuation. Moreover, the shortage of skilled medical professionals, combined with an unfavourable reimbursement scenario in developing and underdeveloped economies, will pose a significant challenge to market growth.

Which Region Dominated the World Alzheimer’s Therapeutic Market?

In 2021, North America has the highest revenue share in the Global Alzheimer's Therapeutic Market and is expected to maintain its dominance throughout the forecast period. The increased spending in R&D activities for the development of technologically advanced techniques and innovative drugs in the treatment of Alzheimer's disease is primarily responsible for revenue growth in the North American market. Moreover, the region's growing geriatric population, rising incidence and prevalence of Alzheimer's disease, expanding healthcare sectors, presence of skilled professionals, and widespread availability of technologically advanced Alzheimer's Therapeutic are major factors driving the Alzheimer's Therapeutic market. For instance, the Journal of the Alzheimer's Association reports that 10.7% of Americans 65 and older, or about 1 in 9 people, in the United States have Alzheimer's dementia. Alzheimer's dementia affects approximately 5% aged 65-74, 13.1% of the population aged 75-84, and 33.2% of the population aged 85 and older.

However, the Asia Pacific market is also expected to expand at a significant rate during the forecast period, owing to an increased focus on the development of healthcare infrastructure and the rising prevalence of Alzheimer's disease in developing countries such as China and India in this region.

Segmentation of Global Alzheimer’s Therapeutic Market -

Global Alzheimer’s Therapeutic Market – By Drug Name

  • Donepezil
  • Rivastigmine
  • Memantine
  • Galantamine
  • Manufactured Combination of Memantine and Donepezil

Global Alzheimer’s Therapeutic Market – By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Manufactured Combination

 Global Alzheimer’s Therapeutic Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Frequently asked questions about the global Alzheimer’s Therapeutic industry

Alzheimer’s Therapeutic market also suffered from COVID 19 pandemic. Some research studies for Alzheimer's disease were put on hold during the pandemic outbreak out of concern for contamination.

North America accounted for the highest share in the global Alzheimer’s Therapeutic market in terms of value as well as volume.

The increased incidence and prevalence of Alzheimer's disease, expanding public health awareness about the condition, and the development of breakthrough technologies and treatments to extend life expectancy are all driving the market.

The cholinesterase inhibitors segment accounts for the biggest revenue share of the Global Alzheimer's Therapeutics market in 2021 and is likely to dominate the market over the forecast period as they are often used by healthcare professionals to treat symptoms linked with memory, thinking, language, judgment, and other thought processes.

Online Pharmacies had a major share in the global market in 2021 and are projected to continue their dominance over the forecast period.

Alzheimer’s Therapeutic Market Scope

Report Attribute Details
Market Value in 2021 USD 2491.5 million
Market Value in 2028 USD 4201.54 million
CAGR 9.1%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Published Date:  Jul 2022
Category:  Pharmaceuticals
Report ID:   57811
Report Format:   PDF
Pages:   190
Rating:    4.8 (70)
Connect With Us
+1-408-641-3282
24/7 Research Support